Contemporary nuclear medicine diagnostics of neuroendocrine tumors

Contemporary nuclear medicine diagnostics of neuroendocrine tumors

The new positron emission tomography (PET/CT) methods for neuroendocrine tumors detection are presented and compared with classic, conventional methods. Conventional methods use a gamma scintillation camera for patients with neuroendocrine tumor imaging, after intravenous injection of one o...

Full description

Bibliographic Details
Main Authors:	Todorović-Tirnanić Mila, Artiko Vera, Pavlović Smiljana, Šobić-Šaranović Dragana, Obradović Vladimir
Format:	Article
Language:	English
Published:	Serbian Medical Society 2015-01-01
Series:	Srpski Arhiv za Celokupno Lekarstvo
Subjects:	neuroendocrine tumors 68Ga-DOTATOC 18F-DOPA 18FDG 6-18F-fluorodopamine 11C-5-hydroxytryptophan
Online Access:	http://www.doiserbia.nb.rs/img/doi/0370-8179/2015/0370-81791502108T.pdf

Similar Items

Cutting-Edge Imaging of Cardiac Metastases from Neuroendocrine Tumors: Lesson from a Case Series
by: Soraya El Ghannudi, et al.
Published: (2022-05-01)

Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging
by: Elise M Blanchet, et al.
Published: (2012-01-01)

Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake
by: Matteo Bauckneht, et al.
Published: (2021-03-01)

The potential application of MR-derived ADCmin values from 68Ga-DOTATATE and 18F-FDG dual tracer PET/MR as replacements for FDG PET in assessment of grade and stage of pancreatic neuroendocrine tumors
by: Jing Gao, et al.
Published: (2023-02-01)

Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
by: Umut Elboga, et al.
Published: (2022-02-01)

Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms
by: Paola Mapelli, et al.
Published: (2021-01-01)

Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors
by: Diletta Calabrò, et al.
Published: (2020-12-01)

Clinical relevance of 18F-FDG PET/CT in the postoperative follow-up of patients with history of medullary thyroid cancer
by: Saponjski Jelena, et al.
Published: (2020-11-01)

A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3)
by: Alice Laffi, et al.
Published: (2021-12-01)

Preparation and Evaluation of [<sup>18</sup>F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [<sup>68</sup>Ga]Ga-DOTA/NOTA-NOC
by: Johan Hygum Dam, et al.
Published: (2022-10-01)

Pulmonary large cell neuroendocrine carcinoma (LCNEC) with confirmed liver metastases negative on 18F-FDG and 68Ga-DOTATATE PET
by: Gaia Ninatti, et al.
Published: (2020-12-01)

F-18 FDG PET/CT imaging of primary hepatic neuroendocrine tumor
by: Katsuya Mitamura, et al.
Published: (2015-01-01)

F-18 FDG PET/CT imaging of primary hepatic neuroendocrine tumor
by: Katsuya Mitamura, et al.
Published: (2015-01-01)

Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update
by: Daniela Prosperi, et al.
Published: (2022-11-01)

Diagnostic Utility of PET CT in Thymic Tumours with Emphasis on 68Ga-DOTATATE PET CT in Thymic Neuroendocrine Tumour - Experience at a Tertiary Level Hospital in India
by: Julie Hephzibah, et al.
Published: (2014-09-01)

Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?
by: Eric Ouvrard, et al.
Published: (2024-01-01)

Hepatic perivascular epithelioid cell tumor resembling hepatic adenoma and hepatocellular carcinoma on preoperative imaging: a case report
by: Dongling Zhu, et al.
Published: (2024-02-01)

Elastofibroma Dorsi: Positron Emission Tomography/Computed Tomography Perspective
by: Tamer Aksoy
Published: (2019-09-01)

The utility of 18F-FDG PET/CT in the diagnosis, staging of non-functioning pancreatic neuroendocrine tumors
by: Gihan Hassan Gamal
Published: (2021-09-01)

Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors
by: Zhihao Zhou, et al.
Published: (2021-09-01)

Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis
by: Natalia Fulle, et al.
Published: (2022-12-01)

Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia
by: Yiping Shi, et al.
Published: (2021-03-01)

The Heterogeneous Metabolic Patterns of Ganglia in 68Ga-PSMA, 11C-choline, and 18F-FDG PET/CT in Prostate Cancer Patients
by: Yiping Shi, et al.
Published: (2021-04-01)

Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
by: Katrin Resch, et al.
Published: (2022-07-01)

Hybrid imaging of vascular graft infection by positron emission tomography with computed tomography using fluorine-18-labeled fluorodeoxyglucose: The Serbian National PET Center experience
by: Šaponjski Jelena, et al.
Published: (2019-01-01)

Clinical Utility of <sup>18</sup>F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis
by: Emmanouil Alevroudis, et al.
Published: (2021-04-01)

What Does PET Imaging Bring to Neuro-Oncology in 2022? A Review
by: Jules Tianyu Zhang-Yin, et al.
Published: (2022-02-01)

The Role of Molecular Imaging in Patients with Brain Metastases: A Literature Review
by: Luca Urso, et al.
Published: (2023-04-01)

Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review
by: Daria Ryzhkova, et al.
Published: (2022-09-01)

Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma
by: Abhishek Jha, et al.
Published: (2019-02-01)

Potential usefulness of 68Ga-citrate PET/CT in detecting infected lower limb prostheses
by: Jing-Ren Tseng, et al.
Published: (2019-01-01)

CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas
by: Alexander Weich, et al.
Published: (2021-03-01)

Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
by: Lennert Boeckxstaens, et al.
Published: (2023-06-01)

[68Ga]Ga-FAPI-04 PET MRI/CT in the evaluation of gastric carcinomas compared with [18F]-FDG PET MRI/CT: a meta-analysis
by: Yawen Wang, et al.
Published: (2023-01-01)

Head-to-head comparison of 18F-FDG and 18F-FES PET/CT for initial staging of ER-positive breast cancer patients
by: Peerapon Kiatkittikul, et al.
Published: (2023-12-01)

Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study
by: Steve Durante, et al.
Published: (2020-05-01)

Comparison of 18F‐FDG PET/CT and 68Ga‐DOTATATE PET/CT in the Targeted Imaging of Culprit Tumors Causing Osteomalacia
by: Hao‐nan Yu, et al.
Published: (2021-05-01)

Diagnostic utility of 68Ga-citrate and 18FDG PET/CT in sarcoidosis patients
by: Cuneyt Tetikkurt, et al.
Published: (2020-12-01)

The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer
by: Kai Shen, et al.
Published: (2021-07-01)

The role of 18FDG PET/CT in evaluation of unknown primary tumors
by: Marković Bogdan, et al.
Published: (2019-01-01)